Sintilimab before and after surgery for head and neck cancer
Part of Cancer clinical trials.
This trial tests a drug called sintilimab (an immunotherapy that boosts your immune system to fight cancer) given before and after surgery for head and neck cancer that can be removed. The goal is to see if adding sintilimab to surgery helps reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer that can be removed with surgery (oral, oropharyngeal, hypopharyngeal, or laryngeal cancer).
- Your cancer is stage III or IVA (locally advanced) and you have not received any prior cancer treatment.
- You are at least 18 years old, with good enough organ function (kidneys, liver, blood counts) to handle the study drug.
- You have no active autoimmune disease or condition requiring strong immune-suppressing medication.
- You do not have distant metastasis, other cancers (except certain skin cancers), or active infections like HIV, hepatitis B/C, or TB.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (IBI110 and sintilimab) with chemotherapy before surgery for people with advanced head and neck cancer that can be removed surgically. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests whether adding two immunotherapy drugs (sintilimab and cetuximab) before and after surgery can improve outcomes for people with advanced mouth or throat cancer. It is for those who have not yet had treatment and whose tumors have a certain protein level (PD-L1 CPS >1).
This trial compares two immunotherapy drugs (ivonescimab vs. pembrolizumab) given before and after surgery for head and neck cancer that can be surgically removed. The goal is to see which drug works better to shrink the tumor and prevent the cancer from coming back.
This trial tests a combination of an immunotherapy drug (sintilimab) with radiation and chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hear when a new Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.